Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
ID: BARDA-CBRN-10302024Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEBARDA - ASPR / DAAPPO / BARDA DCMAWASHINGTON, DC, 20515, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/00fa7a6f61f64bb09fa0abe67931c08d/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking information from potential partners regarding the development of vaccines for the Marburg virus (MARV) and Sudan virus (SUDV). This Sources Sought Notice (SSN) aims to gather insights on vaccine candidates, particularly those that are in or beyond Phase 2 clinical trials, to enhance BARDA's understanding of the current marketplace for these critical medical countermeasures. The development of effective vaccines against MARV and SUDV is vital for preparing for potential public health crises stemming from emerging infectious diseases. Interested parties are encouraged to submit concise responses, limited to ten pages, by November 18, 2024, and can direct inquiries to primary contact Yifan Yang at yifan.yang@hhs.gov or secondary contact Greg Smith at greg.smith1@hhs.gov.

    Point(s) of Contact
    Yifan Yang
    yifan.yang@hhs.gov
    Greg Smith
    greg.smith1@hhs.gov
    Files
    Title
    Posted
    SSN MARV SUDV Vaccines.pdf
    The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, has issued a Sources Sought Notice (SSN) focusing on the development of vaccines for the Marburg virus (MARV) and Sudan virus (SUDV). The purpose of this SSN is to gather information from potential partners regarding their vaccine candidates, particularly those in or beyond Phase 2 clinical trials. Responses are sought from both large and small businesses, aiming to enhance BARDA’s understanding of the current marketplace for these medical countermeasures. Key information requested includes an overview of vaccine candidates, details on clinical development status, nonclinical studies, and manufacturing processes. The document specifies that responses should be concise, limited to a total of ten pages, and submitted by November 18, 2024. It also outlines that this request is purely informational and does not commit the government to any contract obligations. As part of its mission to address threats from emerging infectious diseases, BARDA emphasizes the importance of developing effective vaccines against MARV and SUDV to prepare for potential public health crises.
    Lifecycle
    Title
    Type
    Marburg virus (MARV) and Sudan virus (SUDV) Vaccines
    Currently viewing
    Sources Sought
    Similar Opportunities
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals for the "NextGen Oral Formulation Vaccines for COVID-19" under the Rapid Response Partnership Vehicle (RRPV) Consortium. The objective of this initiative is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, enhancing understanding of their potential and improving COVID-19 solutions to bolster preparedness against future health security threats. This effort is critical in the ongoing response to the COVID-19 pandemic and aims to develop innovative vaccine solutions. Interested parties should note that the proposal submission deadline has been extended to November 15, 2024, and can contact Rebecca Harmon at rebecca.harmon@ati.org for further information.
    BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is issuing a Sources Sought Notice to gather information on antibiotics in development for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI) caused by drug-resistant bacteria. This initiative aims to enhance understanding of the antibiotic development landscape and prepare for future procurement to strengthen U.S. emergency response capabilities against CBRN threats and antibiotic resistance. BARDA is particularly interested in details regarding antibiotic candidates, including their clinical indications, development status, manufacturing plans, and commercialization strategies, with submissions due by November 29, 2025. Interested parties should contact Erin Greninger at erin.greninger@hhs.gov or Audrey Glover at audrey.glover@hhs.gov for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to address public health emergencies. The initiative invites submissions across various Areas of Interest (AOIs), including but not limited to vaccine development, diagnostics, and therapeutics for infectious diseases and chemical threats. This program is crucial for enhancing the nation's preparedness against health security threats, particularly in light of recent global health challenges. Interested parties must register on SAM.gov and adhere to specific submission deadlines, with multiple awards anticipated based on scientific merit and funding availability. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    RFI-Transportable Patient Biocontainment, Isolation, and Quarantine Systems
    Active
    Dept Of Defense
    The U.S. Department of Defense seeks innovative solutions for its Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Protection (JPM CBRN Protection) program. The requirement is for transportable biocontainment, isolation, and quarantine (BIQ) systems, or components thereof, to be used across various platforms such as ships, aircraft, wheeled vehicles, and field deployable systems. These systems are crucial in preventing the spread of biological threats and addressing public health emergencies. Modularity, scalability, and compatibility with existing healthcare infrastructure are key attributes the government seeks, along with strict adherence to safety and quality standards. The focus is on finding deployable and sustainable solutions to contain hazardous pathogens, with the potential for multiple system applications across different platforms. An upcoming Innovation Day on October 9th, 2024, will provide an opportunity for interested parties to discuss their technologies and gain a deeper understanding of the government's requirements. Per the request, responses must be submitted via email to Brian Liska at brian.liska@usmc.mil by November 8th, 2024, at 5:00 p.m. EST. The contact email is brian.liska@usmc.mil, and further details can be found on the SAM.gov website.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 NIAID DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing medical countermeasures against infectious diseases. This opportunity encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens, and the creation of direct acting antivirals targeting viruses with pandemic potential. The initiative is critical for enhancing public health responses to emerging infectious threats and includes funding estimates of up to $8.5 million for Research Area 001 and $20 million for Research Area 002, with proposals due to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) platform, starting around November 22, 2024. For further inquiries, interested parties may contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov.
    Sources Sought-BioFire Reagents and Test Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is conducting a Sources Sought announcement to identify potential qualified small businesses capable of supplying BioFire Defense reagents and test kits. The NIH's Department of Laboratory Medicine requires these reagents for their BioFire FilmArray analyzers, which are essential for the rapid detection of infectious agents from clinical samples, thereby facilitating timely treatment. Interested vendors must submit their company information, including a capability statement, by 12:00 PM EST on November 7, 2024, to Sheri Eiri at sheri.eiri@nih.gov, as the government will not reimburse any costs associated with this request.
    Procurement of storage and stability services to maintain BARDA’s supply of Live Attenuated Influenza Virus Master and Working Seed Lots
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS), specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking to procure storage and stability services for maintaining its supply of Live Attenuated Influenza Virus Master and Working Seed Lots. The procurement aims to ensure that these seed lots remain within specification for use in clinical trials or commercial drug production, which is critical for pandemic preparedness. The contract will be awarded on a sole source basis to MedImmune, LLC, which has been performing these services under a previous indefinite-delivery, indefinite-quantity contract since 2016. Interested parties may submit capability statements or quotations for consideration, and inquiries can be directed to Deitra Williams at deitra.williams@hhs.gov or Corneilus Stephens at corneilus.stephens@hhs.gov.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    Solicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) is seeking proposals for various health research and development services. This opportunity is typically used for experimental development and healthcare services. The place of performance is in the USA. For more information, please contact BARDA-BAA@hhs.gov. The deadline for proposal submission is September 25, 2028, at 4:30 PM Eastern Time.
    Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) Partnership Solicitation, aimed at establishing partnerships with organizations that provide decentralized healthcare services or have decentralized clinical research capabilities. The initiative focuses on enhancing clinical trial capabilities and medical countermeasure (MCM) development, particularly during public health emergencies, by building a sustainable decentralized clinical research infrastructure. With an anticipated funding amount of up to $100 million distributed over a five-year performance period, proposals are due by December 9, 2024, at 12:00 PM EST. Interested parties can direct inquiries to LaunchOfficeContracting@hhs.gov for proposal submissions and additional information.